Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) EBT (2019 - 2025)

Goldenwell Biotech's EBT history spans 7 years, with the latest figure at -$7985.0 for Q3 2025.

  • For Q3 2025, EBT rose 65.38% year-over-year to -$7985.0; the TTM value through Sep 2025 reached $20383.0, up 116.33%, while the annual FY2024 figure was -$131498.0, 12.05% down from the prior year.
  • EBT reached -$7985.0 in Q3 2025 per GWLL's latest filing, down from -$5220.0 in the prior quarter.
  • In the past five years, EBT ranged from a high of $67965.0 in Q4 2024 to a low of -$920332.0 in Q4 2022.
  • Average EBT over 5 years is -$68627.5, with a median of -$27084.0 recorded in 2023.
  • Peak YoY movement for EBT: crashed 16234.25% in 2021, then soared 426.77% in 2024.
  • A 5-year view of EBT shows it stood at -$29554.0 in 2021, then plummeted by 3014.07% to -$920332.0 in 2022, then skyrocketed by 97.74% to -$20799.0 in 2023, then skyrocketed by 426.77% to $67965.0 in 2024, then crashed by 111.75% to -$7985.0 in 2025.
  • Per Business Quant, the three most recent readings for GWLL's EBT are -$7985.0 (Q3 2025), -$5220.0 (Q2 2025), and -$34377.0 (Q1 2025).